ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Oncolytics Biotech, Roche, AIO Initiate Gastrointestinal Cancer Trial americanpharmaceuticalreview
November 05, 2020Oncolytics Biotech? announced a new multi-indication gastrointestinal (GI) cancer study to be managed by AIO. The phase 1/2 trial, known as GOBLET, will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor ... -
Oncolytics Biotech Announces First Patient Treated in MUK Eleven Study
americanpharmaceuticacreview
September 15, 2017REOLYSIN is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class systemically delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. -
Oncolytics Biotech Announces FDA Fast Track for Reolysin
americanpharmaceuticalreview
May 09, 2017Oncolytics Biotech announced the United States Food and Drug Administration (FDA) granted Fast Track designation for Reolysin, the company's proprietary immuno-oncology viral agent, for the treatment of metastatic breast cancer.
Pharma Sources Insight January 2025
